Pro-Apoptotic Breast Cancer Nanotherapeutics
Annual summary rept. 1 Jul 2012-30 Jun 2013
NORTHWESTERN UNIV EVANSTON IL
Pagination or Media Count:
In the past year the DOD BRCP CDMRP Postdoctoral Fellowship has supported my training in translational breast cancer research as part of an interdisciplinary team of scientists using nanotechnology to develop new therapies for breast cancer that activate apoptosis in breast tumor cells. As a member of the Northwestern University Robert H. Lurie Comprehensive Cancer Center I have been able to participate in exciting lecture series and conferences as well as obtain further training in biologic techniques from Cancer Center Core facilities to study cancer biology. I have been working to develop pro-apoptotic nanotherapeutics directed against basal-like breast cancer using a novel nanotechnology platform pioneered by my mentor Prof. Stupp. Our original plan was to combine nanoparticles that induce breast cancer apoptosis through the actions of pro-apoptotic Smac and Trail peptides we have focused on Trail given our success using this peptide to target and kill cancer cells. Accomplishments include 1 We have further refined biologically active Trail peptide amphiphile PA nanofibers and shown similar binding characteristic to the target receptor 2 We have coassembled Trail PAs with PEGylated PAs and encapsulated paclitaxel to construct a multivalent targeted chemotherapeutic 3 We have demonstrated efficacy of the proapoptotic nanoparticles using a mouse model of basal-like breast cancer.
- Medicine and Medical Research